US Patent

US9693989 — N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Method of Use · Assigned to Array Biopharma Inc · Expires 2027-05-09 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds that inhibit a specific type of enzyme and methods of using them to treat diseases characterized by excessive cell growth in mammals.

USPTO Abstract

This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 2 , R 3 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

Drugs covered by this patent

Tukysa (tucatinib) · Seagen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2788`	—	Tukysa
`U-2788`	—	Tukysa

Patent Metadata

Patent number: US9693989
Jurisdiction: US
Classification: Method of Use
Expires: 2027-05-09
Drug substance claim: No
Drug product claim: Yes
Assignee: Array Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.